The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Annouces it Has Been Awarded a Phase II STTR Grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as the PI, Entitled "Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT"

 

Doylestown, PA. Augst 15, 2016- FCCDC is pleased to announce that it has been awarded a Phase II STTR grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as the Principal Investigator (R42HL123126-02). The Project Title is "Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT.”